Search

Your search keyword '"Archambault, Robert"' showing total 29 results

Search Constraints

Start Over You searched for: Author "Archambault, Robert" Remove constraint Author: "Archambault, Robert"
29 results on '"Archambault, Robert"'

Search Results

8. Testosterone recovery in patients with prostate cancer treated with radiotherapy and different ADT duration: Long-term data from two randomized trials.

9. 109: Prostate Cancer-Specific Death Rates in Localized Prostate Cancer: Data from Two Randomized Trials

11. Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial

12. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients

13. 115 Optimal Hypofractionated Rectal Dose-Volume Constraint from the Prostate Cancer Patients of the PCS V Trial

14. 24 Subsequent Androgen Deprivation Therapy After Initial Treatment in Intermediate Risk Prostate Cancer: Prospective Data from a Phase III Trial

15. 125 Rectal Wall Versus Whole Rectum Dose: Which Volume Better Predicts Gastrointestinal Toxicity from Prostate External Beam Radiotherapy?

16. 199 The Clinical Significance of Bone Mineral Density Changes Following Long Term Androgen Deprivation Therapy in Prostate Cancer Patients Enrolled in the PCS V Trial

17. Hypofractionated, dose escalation radiotherapy for high-risk prostate cancer: The primary endpoint of a group led phase III trial. (PCS5).

18. Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial.

19. Is there a relationship between testosterone levels at the end of short-term androgen deprivation therapy and outcomes in intermediate risk prostate cancer? Prospective data from a phase III trial.

20. Causes of death in intermediate- and high-risk prostate cancer treated with radiotherapy with or without androgen deprivation therapy: Analysis from two phase III trials.

25. High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study.

26. 724 TESTOSTERONE RECOVERY IN PATIENTS WITH HIGH RISK PROSTATE CANCER TREATED WITH 36 VS 18 MONTHS OF ANDROGEN BLOCKADE AND PELVIC IRRADIATION

27. Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial.

29. 43 Does Testosterone Recovery After Androgen Deprivation Therapy Impact on Overall Survival in Patients Cured from Prostate Cancer? Long-Term Prospective Data.

Catalog

Books, media, physical & digital resources